Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 43rd Annual J.P.

Fintel reports that on January 8, 2025, TD Cowen upgraded their outlook for Sana Biotechnology (NasdaqGS:SANA) from Hold to ...

Sana Biotechnology (SANA) stock soared after Phase 1 data for its cell therapy which, according to Morgan Stanley, has ...

Sana Biotechnology Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -68.45%. The profit margin, also known as the revenue ratio or gross profit ratio ...

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable [clinical] result” cheered Wall Street, ...

Shares of Sana Biotechnology Inc. (NASDAQ: SANA) were trading at $4.97, up $3.32, or 201%, on first results from an investigator-sponsored, first-in-human study transplanting UP-421, an allogeneic ...

Sana Biotechnology Inc.'s stock soared over 200% on Wednesday, on track to mark its best day on record, amid trading volumes ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

For the first time, a patient with type 1 diabetes has undergone an islet transplantation using genetically modified ...

The Japanese December Household Confidence arrived at 36.2, weaker than expectations of 36.6. Pre-Market U.S. Stock Movers Sana Biotechnology (SANA) spiked about +217% in pre-market trading after ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...